Peringatan Keamanan

The subcutaneous and intravenous lethal dose (LD) in rats are 1000 µg/m3 and 300 µg/m3, respectively.L42605

Few post-marketing reports illustrate cases of medication errors where patients accidentally received up to a single 800 mcg dose of teriparatide, which is 40 times the recommended dose. Patients experienced nausea, weakness or lethargy, and hypotension. No deaths have been reported from teriparatide overdose. Additional signs, symptoms, and complications of overdosage may include a delayed hypercalcemic effect, vomiting, dizziness, and headache.L42590

There is no specific antidote for a teriparatide overdosage. Treatment of suspected overdosage should include discontinuation of teriparatide, monitoring of serum calcium and phosphorus, and implementation of appropriate supportive measures, such as hydration.L42590

Teriparatide

DB06285

biotech approved investigational

Deskripsi

Teriparatide is a recombinant parathyroid hormone (PTH) analog and a potent osteoanabolic agent.A251395 It is made up of the first amino(N)-terminal 34 amino acids of the human PTH.A251395 First approved in the United States in November 2002 and in Europe in April 2003,A251400 teriparatide makes the first approved drug in a new category of osteoporosis therapy called anabolic therapy.A251395 Teriparatide is used in the treatment of osteoporosis in men and women.L42590, L42595

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The half-life of teriparatide in serum was approximately one hour following subcutaneous administration.[L42590]
Volume Distribusi The volume of distribution following intravenous injection is approximately 0.12 L/kg. Teriparatide is not expected to accumulate in bone or other tissues.[L42590]
Klirens (Clearance) Systemic clearance of teriparatide is approximately 62 L/hour in women and 94 L/hour in men. It exceeds the rate of normal liver plasma flow, consistent with both hepatic and extra-hepatic clearance.[L42590]

Absorpsi

The absolute bioavailability is approximately 95%. The peptide reaches peak serum concentrations about 30 minutes after subcutaneous injection of a 20 mcg dose and declines to non-quantifiable concentrations within three hours.L42590

Metabolisme

No metabolism studies have been performed with teriparatide. Peripheral metabolism of PTH is believed to occur by non-specific enzymatic mechanisms in the liver.L42590

Rute Eliminasi

No excretion studies have been performed with teriparatide. It is believed to be excreted via the kidneys.L42590

Interaksi Makanan

1 Data
  • 1. Take with or without food.

Interaksi Obat

194 Data
Fluvoxamine The therapeutic efficacy of Teriparatide can be decreased when used in combination with Fluvoxamine.
Citalopram The therapeutic efficacy of Teriparatide can be decreased when used in combination with Citalopram.
Fluoxetine The therapeutic efficacy of Teriparatide can be decreased when used in combination with Fluoxetine.
Duloxetine The therapeutic efficacy of Teriparatide can be decreased when used in combination with Duloxetine.
Trazodone The therapeutic efficacy of Teriparatide can be decreased when used in combination with Trazodone.
Paroxetine The therapeutic efficacy of Teriparatide can be decreased when used in combination with Paroxetine.
Sertraline The therapeutic efficacy of Teriparatide can be decreased when used in combination with Sertraline.
Sibutramine The therapeutic efficacy of Teriparatide can be decreased when used in combination with Sibutramine.
Nefazodone The therapeutic efficacy of Teriparatide can be decreased when used in combination with Nefazodone.
Escitalopram The therapeutic efficacy of Teriparatide can be decreased when used in combination with Escitalopram.
Zimelidine The therapeutic efficacy of Teriparatide can be decreased when used in combination with Zimelidine.
Dapoxetine The therapeutic efficacy of Teriparatide can be decreased when used in combination with Dapoxetine.
Milnacipran The therapeutic efficacy of Teriparatide can be decreased when used in combination with Milnacipran.
Desvenlafaxine The therapeutic efficacy of Teriparatide can be decreased when used in combination with Desvenlafaxine.
Seproxetine The therapeutic efficacy of Teriparatide can be decreased when used in combination with Seproxetine.
Indalpine The therapeutic efficacy of Teriparatide can be decreased when used in combination with Indalpine.
Ritanserin The therapeutic efficacy of Teriparatide can be decreased when used in combination with Ritanserin.
Alaproclate The therapeutic efficacy of Teriparatide can be decreased when used in combination with Alaproclate.
Amphetamine The risk or severity of adverse effects can be increased when Amphetamine is combined with Teriparatide.
Phentermine The risk or severity of adverse effects can be increased when Phentermine is combined with Teriparatide.
Midodrine The risk or severity of adverse effects can be increased when Midodrine is combined with Teriparatide.
Norepinephrine The risk or severity of adverse effects can be increased when Norepinephrine is combined with Teriparatide.
Phenylephrine The risk or severity of adverse effects can be increased when Phenylephrine is combined with Teriparatide.
Phenylpropanolamine The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Teriparatide.
Metaraminol The risk or severity of adverse effects can be increased when Metaraminol is combined with Teriparatide.
Epinephrine The risk or severity of adverse effects can be increased when Epinephrine is combined with Teriparatide.
Methoxamine The risk or severity of adverse effects can be increased when Methoxamine is combined with Teriparatide.
Orciprenaline The risk or severity of adverse effects can be increased when Orciprenaline is combined with Teriparatide.
Phenmetrazine The risk or severity of adverse effects can be increased when Phenmetrazine is combined with Teriparatide.
Dobutamine The risk or severity of adverse effects can be increased when Dobutamine is combined with Teriparatide.
Pseudoephedrine The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Teriparatide.
Benzphetamine The risk or severity of adverse effects can be increased when Benzphetamine is combined with Teriparatide.
Ritodrine The risk or severity of adverse effects can be increased when Ritodrine is combined with Teriparatide.
Terbutaline The risk or severity of adverse effects can be increased when Terbutaline is combined with Teriparatide.
Oxymetazoline The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Teriparatide.
Diethylpropion The risk or severity of adverse effects can be increased when Diethylpropion is combined with Teriparatide.
Dopamine The risk or severity of adverse effects can be increased when Dopamine is combined with Teriparatide.
Isoprenaline The risk or severity of adverse effects can be increased when Isoprenaline is combined with Teriparatide.
Lisdexamfetamine The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Teriparatide.
Fenoterol The risk or severity of adverse effects can be increased when Fenoterol is combined with Teriparatide.
Ephedrine The risk or severity of adverse effects can be increased when Ephedrine is combined with Teriparatide.
Mephentermine The risk or severity of adverse effects can be increased when Mephentermine is combined with Teriparatide.
Procaterol The risk or severity of adverse effects can be increased when Procaterol is combined with Teriparatide.
Clenbuterol The risk or severity of adverse effects can be increased when Clenbuterol is combined with Teriparatide.
MMDA The risk or severity of adverse effects can be increased when MMDA is combined with Teriparatide.
Midomafetamine The risk or severity of adverse effects can be increased when Midomafetamine is combined with Teriparatide.
2,5-Dimethoxy-4-ethylamphetamine The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Teriparatide.
4-Bromo-2,5-dimethoxyamphetamine The risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Teriparatide.
Tenamfetamine The risk or severity of adverse effects can be increased when Tenamfetamine is combined with Teriparatide.
Chlorphentermine The risk or severity of adverse effects can be increased when Chlorphentermine is combined with Teriparatide.
Methylenedioxyethamphetamine The risk or severity of adverse effects can be increased when Methylenedioxyethamphetamine is combined with Teriparatide.
Dextroamphetamine The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with Teriparatide.
Metamfetamine The risk or severity of adverse effects can be increased when Metamfetamine is combined with Teriparatide.
Nylidrin The risk or severity of adverse effects can be increased when Nylidrin is combined with Teriparatide.
Tetryzoline The risk or severity of adverse effects can be increased when Tetryzoline is combined with Teriparatide.
Tyramine The risk or severity of adverse effects can be increased when Tyramine is combined with Teriparatide.
Isoxsuprine The risk or severity of adverse effects can be increased when Isoxsuprine is combined with Teriparatide.
Etilefrine The risk or severity of adverse effects can be increased when Etilefrine is combined with Teriparatide.
Synephrine The risk or severity of adverse effects can be increased when Synephrine is combined with Teriparatide.
Iofetamine I-123 The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Teriparatide.
Racepinephrine The risk or severity of adverse effects can be increased when Racepinephrine is combined with Teriparatide.
Ritobegron The risk or severity of adverse effects can be increased when Ritobegron is combined with Teriparatide.
Tramazoline The risk or severity of adverse effects can be increased when Tramazoline is combined with Teriparatide.
Mephedrone The risk or severity of adverse effects can be increased when Mephedrone is combined with Teriparatide.
Fenozolone The risk or severity of adverse effects can be increased when Fenozolone is combined with Teriparatide.
Methoxyphenamine The risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Teriparatide.
Tretoquinol The risk or severity of adverse effects can be increased when Tretoquinol is combined with Teriparatide.
Gepefrine The risk or severity of adverse effects can be increased when Gepefrine is combined with Teriparatide.
Prenalterol The risk or severity of adverse effects can be increased when Prenalterol is combined with Teriparatide.
Mefenorex The risk or severity of adverse effects can be increased when Mefenorex is combined with Teriparatide.
2,5-Dimethoxy-4-ethylthioamphetamine The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Teriparatide.
Labetalol The risk or severity of adverse effects can be increased when Labetalol is combined with Teriparatide.
Acebutolol The risk or severity of adverse effects can be increased when Acebutolol is combined with Teriparatide.
Celiprolol The risk or severity of adverse effects can be increased when Celiprolol is combined with Teriparatide.
Bucindolol The risk or severity of adverse effects can be increased when Bucindolol is combined with Teriparatide.
Epanolol The risk or severity of adverse effects can be increased when Epanolol is combined with Teriparatide.
Gefitinib The therapeutic efficacy of Teriparatide can be decreased when used in combination with Gefitinib.
Sorafenib The therapeutic efficacy of Teriparatide can be decreased when used in combination with Sorafenib.
Erlotinib The therapeutic efficacy of Teriparatide can be decreased when used in combination with Erlotinib.
Imatinib The therapeutic efficacy of Teriparatide can be decreased when used in combination with Imatinib.
Dasatinib The therapeutic efficacy of Teriparatide can be decreased when used in combination with Dasatinib.
Lapatinib The therapeutic efficacy of Teriparatide can be decreased when used in combination with Lapatinib.
Sunitinib The therapeutic efficacy of Teriparatide can be decreased when used in combination with Sunitinib.
Genistein The therapeutic efficacy of Teriparatide can be decreased when used in combination with Genistein.
3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone The therapeutic efficacy of Teriparatide can be decreased when used in combination with 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone.
Geldanamycin The therapeutic efficacy of Teriparatide can be decreased when used in combination with Geldanamycin.
PD173955 The therapeutic efficacy of Teriparatide can be decreased when used in combination with PD173955.
Radicicol The therapeutic efficacy of Teriparatide can be decreased when used in combination with Radicicol.
Cediranib The therapeutic efficacy of Teriparatide can be decreased when used in combination with Cediranib.
Nilotinib The therapeutic efficacy of Teriparatide can be decreased when used in combination with Nilotinib.
Vatalanib The therapeutic efficacy of Teriparatide can be decreased when used in combination with Vatalanib.
Vandetanib The therapeutic efficacy of Teriparatide can be decreased when used in combination with Vandetanib.
Canertinib The therapeutic efficacy of Teriparatide can be decreased when used in combination with Canertinib.
Tandutinib The therapeutic efficacy of Teriparatide can be decreased when used in combination with Tandutinib.
Motesanib The therapeutic efficacy of Teriparatide can be decreased when used in combination with Motesanib.
Dovitinib The therapeutic efficacy of Teriparatide can be decreased when used in combination with Dovitinib.
Glesatinib The therapeutic efficacy of Teriparatide can be decreased when used in combination with Glesatinib.
Lestaurtinib The therapeutic efficacy of Teriparatide can be decreased when used in combination with Lestaurtinib.
Pazopanib The therapeutic efficacy of Teriparatide can be decreased when used in combination with Pazopanib.
Midostaurin The therapeutic efficacy of Teriparatide can be decreased when used in combination with Midostaurin.

Target Protein

Parathyroid hormone PTH
Parathyroid hormone/parathyroid hormone-related peptide receptor PTH1R

Referensi & Sumber

Artikel (PubMed)
  • PMID: 18319498
    Stroup J, Kane MP, Abu-Baker AM: Teriparatide in the treatment of osteoporosis. Am J Health Syst Pharm. 2008 Mar 15;65(6):532-9. doi: 10.2146/ajhp070171.
  • PMID: 32644674
    Vall H, Parmar M: Teriparatide .
  • PMID: 15262455
    Quattrocchi E, Kourlas H: Teriparatide: a review. Clin Ther. 2004 Jun;26(6):841-54. doi: 10.1016/s0149-2918(04)90128-2.

Contoh Produk & Brand

Produk: 34 • International brands: 1
Produk
  • Apo-teriparatide Injection
    Solution • 250 mcg / mL • Subcutaneous • Canada • Generic • Approved
  • Forsteo
    Injection, solution • 20 μg/80μl • Subcutaneous • EU • Approved
  • Forsteo
    Injection, solution • 20 μg/80μl • Subcutaneous • EU • Approved
  • Forteo
    Injection, solution • 250 ug/1mL • Subcutaneous • US • Approved
  • Forteo
    Injection, solution • 750 ug/3mL • Subcutaneous • US • Approved
  • Forteo
    Injection, solution • 250 ug/1mL • Subcutaneous • US • Approved
  • Forteo
    Solution • 250 mcg / mL • Subcutaneous • Canada • Approved
  • Kauliv
    Injection, solution • 20 µg/80µl • - • EU • Approved
Menampilkan 8 dari 34 produk.
International Brands
  • Forsteo — Eli Lilly and Company

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul